Aspira Women's Health
Biotechnology ResearchView the employees at
Aspira Women's Health-
Chad Wise, B.S. Sales Leader
-
Top 5%
Nick Tjoumas Integration Engineer at Aspira Women's Health-
Centreville, Virginia, United States
-
Rising Star
Jessica Hooks Greenwood Senior Director of Clinical Implementation and Innovation at Aspira Women's Health-
Alexandria, Virginia, United States
-
Rising Star
Carla Phipps Quality Assurance Manager at Vermillion, Inc.-
Wichita, Kansas, United States
-
Rising Star
Jannie Herchuk Qualified Financial Expert | NACD Directorship Certified® | Retired Senior Partner at Deloitte-
Dallas, Texas, United States
-
Rising Star
Overview
Aspira Women’s Health Inc. is transforming women’s gynecological health with the discovery, development, and commercialization of innovative testing options for women of all races and ethnicities, starting with ovarian cancer. Our ovarian cancer risk assessment portfolio is marketed to healthcare providers as OvaSuite℠, which includes OvaWatch℠, a non-invasive, blood-based test intended for use in the initial clinical assessment of ovarian cancer risk in women with benign or indeterminate adnexal masses for which surgical intervention may be either premature or unnecessary. With a negative predictive value (NPV) of 99%, OvaWatch allows physicians to confidently rule out ovarian cancer malignancy and choose the appropriate clinical management for the right patient at the right time. Ova1Plus® combines our FDA-cleared products, Ova1® and Overa®, to detect risk of ovarian malignancy in women with adnexal masses planned for surgery. EndoCheck℠, Aspira’s first-of-its-kind non-invasive diagnostic test for endometriosis, is currently in development. Visit our website for more information at www.aspirawh.com.
-